Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

British Journal of Cancer
Jim CassidyL P Garrison

Abstract

Oral capecitabine (Xeloda) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not yet approved by the UK National Institute for Health and Clinical Excellence (NICE) in the adjuvant setting. Adjuvant capecitabine is at least as effective as 5-fluorouracil/leucovorin (5-FU/LV), with significant superiority in relapse-free survival and a trend towards improved disease-free and overall survival. We assessed the cost-effectiveness of adjuvant capecitabine from payer (UK National Health Service (NHS)) and societal perspectives. We used clinical trial data and published sources to estimate incremental direct and societal costs and gains in quality-adjusted life months (QALMs). Acquisition costs were higher for capecitabine than 5-FU/LV, but higher 5-FU/LV administration costs resulted in 57% lower chemotherapy costs for capecitabine. Capecitabine vs 5-FU/LV-associated adverse events required fewer medications and hospitalisations (cost savings pound3653). Societal costs, including patient travel/time costs, were reduced by >75% with capecitabine vs 5-FU/LV (cost savings p...Continue Reading

References

Oct 16, 1996·JAMA : the Journal of the American Medical Association·M C WeinsteinL B Russell
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J O'ConnellH S Wieand
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R PorschenUNKNOWN Arbeitsgemeinschaft Gastrointestinale Onkologie
Apr 6, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C TwelvesUNKNOWN Xeloda Colorectal Cancer Study Group
Jan 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M M BornerP Fumoleau
Feb 28, 2002·The American Journal of Gastroenterology·Scott D RamseyRuth Etzioni
Jul 12, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E Van CutsemH J Schmoll
Feb 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H T ArkenauUNKNOWN Arbeitsgemeinschaft Gastrointestinale Onkologie
Sep 25, 2003·Endocrine-related Cancer·H J Mackay, C J Twelves
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W ScheithauerUNKNOWN X-ACT Study Group
Jul 1, 2005·The New England Journal of Medicine·Chris TwelvesWerner Scheithauer
Nov 24, 2005·Emergency Medicine Australasia : EMA·James MallowsAndis Graudins

❮ Previous
Next ❯

Citations

May 31, 2014·World Journal of Gastroenterology : WJG·Carlos AguadoEduardo Díaz-Rubio
Jun 2, 2011·Cancer Management and Research·Bradford R Hirsch, S Yousuf Zafar
Sep 21, 2011·Cancer Management and Research·H Hameed, J Cassidy
Nov 3, 2012·Patient Preference and Adherence·Lonneke TimmersJacqueline G Hugtenburg
Jan 15, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Mehmet U S AyvaciSam J Lubner
Oct 23, 2009·International Journal of Technology Assessment in Health Care·Paul TappendenHazel Pilgrim
Mar 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V J HarveyM P Findlay
Apr 14, 2012·Drug Metabolism Reviews·Jose J G MarinOscar Briz
Feb 14, 2009·Current Medical Research and Opinion·Nikos ManiadakisGeorge Fountzilas
Nov 26, 2013·Acta Oncologica·Lonneke TimmersJacqueline G Hugtenburg
Jun 10, 2010·Clinical Journal of Oncology Nursing·Mendy Moody, Joyce Jackowski
Oct 7, 2016·Frontiers in Pharmacology·Lonneke TimmersJacqueline G Hugtenburg
Aug 22, 2013·Journal of the National Cancer Institute. Monographs·K Robin YabroffJoseph Lipscomb
Jul 6, 2007·PharmacoEconomics·Frank G A JansmanJacobus R B J Brouwers
Dec 20, 2007·American Journal of Clinical Oncology·Edgar Ben-Josef
Jul 1, 2008·The Patient·Candida M MastroianniUNKNOWN Gruppo Oncologico Calabrese Multidisciplinare (GOCaM)
Mar 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Paula Manchon WalshUNKNOWN Colorectal Cancer OncoGuia Group
Feb 28, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Glynne-JonesD Sebag-Montefiore
Dec 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans-Joachim SchmollDaniel G Haller
Jun 9, 2007·Expert Review of Anticancer Therapy·Claire Kelly, Jim Cassidy
Aug 25, 2006·Clinical Journal of Oncology Nursing·Deborah T Berg
Apr 12, 2008·Expert Review of Anticancer Therapy·Hilary Glen, Jim Cassidy
Apr 12, 2008·Expert Review of Anticancer Therapy·Yu Jo Chua, John R Zalcberg
Jul 13, 2013·Applied Health Economics and Health Policy·Ebenezer Tetteh, Stephen Morris
Jan 1, 2014·European Journal of Cancer Care·C W M van GilsC A Uyl-de Groot
Aug 8, 2014·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Hong-Hwa ChenElise Chia-Hui Tan
Jul 15, 2015·Current Treatment Options in Oncology·Veena Shankaran
May 25, 2016·Cancer Chemotherapy and Pharmacology·James J LeeEdward Chu
Apr 14, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Jennie H Best, Louis P Garrison
Dec 14, 2011·Expert Review of Anticancer Therapy·Janet S Graham, James Cassidy
Jan 1, 2016·Oncology and Therapy·Lourens T BloemMarion Haas
Nov 16, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J M VieitezE Díaz-Rubio
Nov 10, 2007·Current Gastroenterology Reports·Olivia Aranha, Al B Benson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.